Global Multiple Sclerosis Therapeutics Market Overview
Multiple Sclerosis (MS) is condition affects brain and spinal cord, in which nerve coating (myelin) gets damaged and causes a range of symptoms, including problems with vision, arm or leg movement, sensation or balance. Once diagnose, MS stays as a lifelong condition, causing serious disability. MS is most commonly diagnosed in people at 20 to 30 ages, although it can develop at any age. In addition, it is more common among women than men. In MS, resulting nerve damage disrupts communication between the brain and the body. Multiple sclerosis causes many different symptoms, including vision loss, pain, fatigue and impaired coordination. The symptoms, severity and duration can vary from person to person. Some people may be symptom free for most of their lives, while others can have severe, chronic symptoms that never go away. Physiotherapy and medication that suppress the immune system can help with symptoms, and slow disease progression. The Multiple Sclerosis Therapeutics Market accounted for US$ 25.86 billion in 2020 and is estimated to be US$ 46.71 billion by 2030 and is anticipated to register a CAGR of 6.1%.
Global Multiple Sclerosis Therapeutics Market Drivers & Restraints
Increase prevalence of multiple sclerosis
Currently, there is no cure for MS however; number of treatment can help to control the condition. Treatment modalities are depends on specific symptoms and difficulties of patient, which includes treating relapses with short courses of steroid medication, disease modifying therapies, and specific treatments for individual MS symptoms. Increasing prevalence of multiple sclerosis among the global population, along with extensive research and development (R&D) activities undertaken by key players and government research organizations will accelerate the market growth
Global Multiple Sclerosis Therapeutics Market Segmentations & Regional Insights
The multiple sclerosis therapeutics market has been segmented on the basis of drug class, route of administration, distribution channel, and region.
On the basis of drug class, the multiple sclerosis therapeutics market is segmented into beta interferon, corticosteroids, monoclonal antibodies, antineoplastic agents, and others. Route of administration in multiple sclerosis therapeutics market segmented into oral and injectable. Further, the distribution channel for multiple sclerosis therapeutics market includes hospital pharmacies, retail pharmacies, and online pharmacies.
Regional Insights:
On the basis of region, the target market has been segmented into North America, Europe, Asia Pacific, Latin America, Middle East, and Africa.
North America is expected to dominate the multiple sclerosis therapeutics market. Factors responsible for growth of the market includes substantial rise in the awareness among the people regarding various risk factors to cause multiple sclerosis. In addition, high diagnostic rate in the U.S. which leads to significant rise in prescription rates in this region to gain the dominance in the market. Asia Pacific region offers lucrative growth opportunities in multiple sclerosis market, owing to increasing engagement of key players by collaboration with local key players in attempt to capture the market by offering novel treatment therapy, in the region.
Attribute |
Details |
Base year for estimation |
2020 |
Forecast period |
2020 – 2030 |
Market representation |
Revenue in USD Million & CAGR from 2020 – 2030 |
Market Segmentation |
By Drug Class: Beta Interferon, Corticosteroids, Monoclonal Antibodies, Antineoplastic Agents, and Others By Route of Administration: Oral and Injectables By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies |
Regional scope |
North America - U.S., Canada Europe - UK, Germany, Spain, France, Italy, Russia, Rest of Europe Asia Pacific - Japan, India, China, South Korea, Australia, Rest of Asia-Pacific Latin America - Brazil, Mexico, Argentina, Rest of Latin America Middle East & Africa - South Africa, Saudi Arabia, UAE, Rest of Middle East & Africa |
Report coverage |
Revenue forecast, company share, competitive landscape, growth factors, and trends |
Detailed Segmentation:
Multiple Sclerosis Therapeutics Market, By Region:
- North America
- Middle East & Africa
- Middle East & Africa Multiple Sclerosis Therapeutics Market, By Drug Class
- Middle East & Africa Multiple Sclerosis Therapeutics Market, By Route of Administration
- Middle East & Africa Multiple Sclerosis Therapeutics Market, By Distribution Channel Industry
- Middle East & Africa Multiple Sclerosis Therapeutics Market, By Country
- GCC
- Israel
- South Africa
- Rest of Middle East & Africa
- Latin America
- Latin America Multiple Sclerosis Therapeutics Market, By Drug Class
- Latin America Multiple Sclerosis Therapeutics Market, By Route of Administration
- Latin America Multiple Sclerosis Therapeutics Market, By Distribution Channel
- Latin America Multiple Sclerosis Therapeutics Market, By Country
- Brazil
- Mexico
- Rest of Latin America
- Asia Pacific
- Asia Pacific Multiple Sclerosis Therapeutics Market, By Drug Class
- Asia Pacific Multiple Sclerosis Therapeutics Market, By Route of Administration
- Asia Pacific Multiple Sclerosis Therapeutics Market, By Distribution Channel
- Asia Pacific Multiple Sclerosis Therapeutics Market, By Country
- China
- India
- Japan
- South Korea
- Rest of Asia Pacific
- Europe
- Europe Multiple Sclerosis Therapeutics Market, By Drug Class
- Europe Multiple Sclerosis Therapeutics Market, By Route of Administration
- Europe Multiple Sclerosis Therapeutics Market, By Distribution Channel
- Europe Multiple Sclerosis Therapeutics Market, By Country
- Germany
- UK
- France
- Russia
- Italy
- Rest of Europe
- North America Multiple Sclerosis Therapeutics Market, By Drug Class
- North America Multiple Sclerosis Therapeutics Market, By Route of Administration
- North America Multiple Sclerosis Therapeutics Market, By Distribution Channel
- North America Multiple Sclerosis Therapeutics Market, By Country
- The U.S.
- Canada
- Middle East & Africa
Global Multiple Sclerosis Therapeutics Market Competitive Landscape & Key Players
Key players operating in the multiple sclerosis therapeutics market includes Bayer AG, Teva Pharmaceutical Industries Ltd., Novartis AG, Merck KGaA, Biogen Inc., Sanofi S.A., F. Hoffmann-La Roche AG, AbbVie, Inc., and Pfizer, Inc.
Global Multiple Sclerosis Therapeutics Market Company Profile
- Bayer AG
- Pfizer, Inc.
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Performance
- AbbVie, Inc.
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Performance
- F. Hoffmann-La Roche AG
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Performance
- Sanofi S.A.
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Performance
- Biogen Inc.
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Performance
- Merck KGaA
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Performance
- Novartis AG
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Performance
- Teva Pharmaceutical Industries Ltd.
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Performance
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Performance
- Pfizer, Inc.
Global Multiple Sclerosis Therapeutics Market Highlights
FAQs
The Multiple Sclerosis Therapeutics Market has been segmented on the basis of form, material type, end-user industry and region.
Multiple Sclerosis Therapeutics are expected to be cheaper in use in due time than their currently used traditional counterparts because of their increased reliability, low maintenance (fewer inspections and repairs), and longer lifetime.
Europe region dominates the Multiple Sclerosis Therapeutics Market.
Key players in the Multiple Sclerosis Therapeutics Market includes, Acciona S.A., Akzo Nobel N.V., Applied Thin Films, Inc. (ATFI), Autonomic Materials Inc., BASF SE, Covestro AG, Critical Materials S.A., Devan Chemicals N.V., E. I. Du Pont De Nemours and Company, and Sensor Coating Systems Ltd.